Rigel Pharmaceuticals RIGL Accrued research and development
Accrued research and development at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:AccruedResearchAndDevelopmentLiabilityCurrent.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's accrued research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's accrued research and development?
- Rigel Pharmaceuticals (RIGL) reported accrued research and development of $5.74M in Q1 2026.
- How has Rigel Pharmaceuticals's accrued research and development changed year-over-year?
- Rigel Pharmaceuticals's accrued research and development increased by 23.5% year-over-year, from $4.65M to $5.74M.
- What is the long-term trend for Rigel Pharmaceuticals's accrued research and development?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's accrued research and development has grown at a 2.5% compound annual growth rate (CAGR), from $4.89M to $5.52M.
- What does accrued research and development mean?
- This represents the estimated financial obligations incurred for ongoing research and development activities that have not yet been invoiced or paid. It reflects the company's commitment to external service providers, such as clinical research organizations, for work performed but not yet settled. Monitoring this helps assess the near-term cash requirements for the company's R&D pipeline.